Bengaluru, India — December 8, 2025: Biocon Limited announced that its subsidiary, Biocon Biologics, will become a wholly owned subsidiary of the parent company, Biocon Limited, by March 31, 2026.
Following the completion of this integration, Mr. Shreehas Tambe, currently CEO & Managing Director of Biocon Biologics, will take charge as the first CEO & Managing Director of the combined Biocon business, subject to necessary regulatory approvals.
This marks a pivotal step in Biocon’s journey toward building a fully integrated, innovation-led biopharmaceutical company committed to advancing access to high-quality biosimilars and biologics globally.
Contents
A Visionary Leader with Over 28 Years at Biocon
Mr. Shreehas Tambe joined Biocon in 1997 as a Management Trainee and has spent over 28 years contributing to the company’s growth across multiple leadership roles. His career trajectory within Biocon Group is a testament to the organization’s culture of developing talent and fostering long-term leadership.
Over the years, Tambe has shaped strategic initiatives across operations, manufacturing, and business development, driving Biocon Biologics’ expansion and innovation agenda.
His leadership has been instrumental in positioning Biocon Biologics among the Top 5 biosimilars companies globally by revenue, amplifying its presence in international markets and reinforcing India’s position as a global biopharma hub.
The Strategy of “Preserve, Consolidate, and Accelerate”
Tambe’s guiding philosophy, known as the “Preserve, Consolidate, and Accelerate” strategy, has been a cornerstone of Biocon Biologics’ success story.
- Preserve: Retaining Biocon’s core strengths in scientific innovation and patient-centricity.
- Consolidate: Seamlessly integrating acquired assets and optimizing operational efficiency.
- Accelerate: Driving revenue growth, expanding geographic reach, and delivering consistent profitability.
This approach proved critical during the successful integration of the Viatris biosimilars business, which was completed across over 120 countries in record time. The consolidation enhanced Biocon Biologics’ global footprint, creating an agile and unified organization built for scale, sustainability, and long-term growth.
Strengthening Biocon’s Global Leadership in Biosimilars
Under Tambe’s leadership, Biocon Biologics has become a global player in the biosimilars market, offering affordable and high-quality therapies that address chronic diseases such as diabetes, cancer, and autoimmune conditions.
By combining Biocon’s innovative research capabilities with Biocon Biologics’ commercial and manufacturing strengths, the merged entity will be better positioned to accelerate global access to biologic therapies and drive affordable healthcare innovation.
The integration also aligns with Biocon’s ambition to strengthen its biopharma and biosimilar portfolio, expand partnership networks, and enhance supply chain resilience to serve patients globally.
Focus on Sustainable and Profitable Growth
Tambe’s focus on profitable and sustainable growth has led to significant improvement in Biocon Biologics’ financial metrics over recent years. His strategic prioritization of operational excellence, disciplined cost management, and market expansion has reinforced the company’s position as a trusted biosimilar provider worldwide.
The upcoming integration into Biocon Limited will enable a streamlined operational structure, optimize resource allocation, and enhance synergies across research, manufacturing, and commercialization.
A New Phase of Growth for Biocon
This leadership transition reflects Biocon’s commitment to ensuring business continuity, strategic stability, and leadership excellence. The company believes that Tambe’s deep institutional knowledge, technical expertise, and visionary leadership will drive the next era of Biocon’s growth.
Source
Verification: To confirm the legitimacy of this posting, you can view the original announcement on the Biocon LinkedIn page.
Speaking about the transition, Biocon reaffirmed its dedication to advancing global healthcare access and maintaining a strong focus on patients, innovation, and value creation.
About Biocon Limited
Biocon Limited (NSE: BIOCON) is a leading global biopharmaceutical company headquartered in Bengaluru, India. The company focuses on developing innovative and affordable biopharmaceutical solutions across diabetes, oncology, immunology, and specialty areas. With strong R&D capabilities and a robust biosimilars pipeline, Biocon has established a presence in over 120 countries.
About Biocon Biologics
A subsidiary of Biocon Limited, Biocon Biologics is dedicated to developing, manufacturing, and commercializing high-quality biosimilar medicines. Its mission is to enhance patient access to life-saving therapies through innovation, affordability, and global collaboration.
Conclusion
The appointment of Shreehas Tambe as the first CEO & Managing Director of the combined Biocon Limited and Biocon Biologics marks a defining moment in the company’s evolution. This strategic leadership transition symbolizes Biocon’s confidence in its homegrown talent and long-term vision for sustainable, innovation-driven growth.
With his deep-rooted experience, strategic clarity, and proven leadership in global biosimilar markets, Tambe is well-equipped to steer Biocon into a new era of operational excellence and global competitiveness.
As Biocon continues to expand its footprint in over 120 countries, the organization remains steadfast in its mission — to deliver affordable and world-class biopharmaceuticals that transform patient lives worldwide.
